Clinical trials: Lung Cancer Stage I
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Locally Advanced or Metastatic NSCLC
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
This is an open-label phase I/II preliminary study, including dose escalation, dose expansion, and efficacy expansion, to evaluate drug safety, tolerability, PK, and efficacy.
- Trial name
- NCT05662670
- Testing
- WJ13404 tablets
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Suzhou Junjing BioSciences Co., Ltd.
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00080041
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pharmacyclics LLC.
Advanced Cancer, Lung Cancer
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with…
- Conditions
- Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- TIG-006 (NCT05060432)
- Testing
- EOS-448, pembrolizumab, inupadenant
- Where
- 42 sites in United States, Belgium and 4 more
- Volunteers
- 153 people
- Sponsor
- iTeos Belgium SA
Non-Small Cell Lung Cancer With EGFR Mutation
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of CFT8919 capsules in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying…
- Trial name
- NCT06641609
- Testing
- Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8919 capsule
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumors
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC), platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer (TNBC).
- Trial name
- NCT01930292
- Testing
- Part A: Debio 1143, Paclitaxel, Carboplatin
- Where
- 4 sites in France
- Volunteers
- 31 people
- Sponsor
- Debiopharm International SA
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
NSCLC (Non-small Cell Lung Cancer)
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop…
- Trial name
- NCT07063329
- Testing
- PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy, RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 108 people
- Sponsor
- Avistone Pharmaceutical（Ningbo）Co., LTD.
Squamous Cell Lung Cancer
An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)/pharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants…
- Trial name
- NCT07444281
- Testing
- C-CAR031
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai AbelZeta Ltd.
Non-small Cell Lung Cancer, Solid Tumor
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort-expansion, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M09D1 for…
- Trial name
- NCT07056556
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Non-small Cell Lung Cancer (NSCLC)
Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the safety, tolerability, feasibility and preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as single agent or in combination with PDR001…
- Trial name
- AdenONCO (NCT02403193)
- Testing
- PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Palobiofarma SL
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Prostate Cancers, Breast Cancer
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.
- Conditions
- Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer
- Trial name
- ADVICE (NCT06926075)
- Testing
- A novel hGIIA-Vimentin Inhibitor, Dose expansion
- Where
- 3 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Filamon LTD
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without…
- Trial name
- ADAURA (NCT02511106)
- Testing
- AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Where
- 238 sites in United States, Australia and 23 more
- Volunteers
- 682 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Advanced Solid Tumours
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety, pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid tumours where KRAS may be an important driver of…
- Trial name
- NCT03101839
- Testing
- AZD4785
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Pulmonary Diseases, Cardiovascular Diseases
Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)
The purpose of this study is to define the dose for a Phase II study and to investigate safety and tolerability of intravenous administration of recombinant soluble human Angiotensin Converting Enzyme 2 in healthy volunteers.
- Conditions
- Pulmonary Diseases, Cardiovascular Diseases, Kidney Diseases, Cancer Diseases
- Trial name
- NCT00886353
- Testing
- APN01
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Apeiron Biologics
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
- Trial name
- CLOVER (NCT03509012)
- Testing
- Durvalumab, Tremelimumab, Cisplatin (dose level 4)
- Where
- 16 sites in United States, Japan and 3 more
- Volunteers
- 105 people
- Sponsor
- AstraZeneca